Provided by Tiger Trade Technology Pte. Ltd.

CSPC PHARMA

8.270
-0.530-6.02%
Volume:111.50M
Turnover:927.34M
Market Cap:95.29B
PE:22.43
High:8.680
Open:8.640
Low:8.190
Close:8.800
52wk High:11.454
52wk Low:4.463
Shares:11.52B
HK Float Shares:11.52B
Volume Ratio:1.53
T/O Rate:0.97%
Dividend:0.24
Dividend Rate:2.90%
EPS(LYR):0.369
ROE:10.83%
ROA:5.65%
PB:2.52
PE(LYR):22.43
PS:3.20

Loading ...

Earning Preview: CSPC PHARMA this quarter’s revenue is expected to increase by 31.04%, and institutional views are bullish

Earnings Agent
·
Mar 18

BRIEF-CSPC Pharmaceutical Aprepitant Injection (4.4Ml32Mg) Obtains Drug Registration Approval In China

Reuters
·
Yesterday

CSPC Pharma Gets China Nod for Postoperative Nausea Drug Registration

MT Newswires Live
·
Yesterday

CSPC Pharma Gains NMPA Clearance for New-Generation Aprepitant Injection Targeting Post-Operative Nausea

Bulletin Express
·
Yesterday

CSPC PHARMA's Aprepitant Injection Secures Drug Registration Approval

Stock News
·
Yesterday

CSPC wins China NMPA approval for 32mg aprepitant injection

Reuters
·
Yesterday

CSPC Pharmaceutical - Approval Granted by Nmpa

THOMSON REUTERS
·
Yesterday

CSPC Pharmaceutical - Aprepitant Injection (4.4Ml:32Mg) Obtains Drug Registration Approval in China

THOMSON REUTERS
·
Yesterday

CSPC Pharmaceutical Group Stock Sheds 6.0% in Hong Kong, Underperforms Competitors

Dow Jones
·
Yesterday

Zhejiang Starry to Acquire 20% Stake in Ruishi Pharma for 10 Million Yuan to Boost CMO Capacity

Stock News
·
Yesterday

CSPC Pharmaceutical Receives Chinese Clinical Trial Approval for GLP-1/GIP Dual Agonist

Stock News
·
Mar 20

BRIEF-Cspc Pharmaceutical Says GLP-1/GIP Receptor Dual-Biased Agonist Polypeptide Injection Obtains Clinical Trial Approval In China

Reuters
·
Mar 20

CSPC Pharma wins China clinical trial approval for SYH2082 injection

Reuters
·
Mar 20

CSPC Pharmaceutical - Glp-1/Gip Receptor Dual-Biased Agonist Polypeptide Long-Acting Injection (Syh2082 Injection) Obtains Clinical Trial Approval in China

THOMSON REUTERS
·
Mar 20

DIARY-Hong Kong corporate earnings week ahead

Reuters
·
Mar 20

Pharmaceutical Firm Rebrands Following CSPC PHARMA Takeover

Deep News
·
Mar 19

CSPC Pharmaceutical Group Stock Slides 1.8% in Hong Kong, Outperforms Competitors

Dow Jones
·
Mar 19

CSPC Pharmaceutical Group Stock Rises 0.9% in Hong Kong

Dow Jones
·
Mar 17

CSPC PHARMA Subsidiary CSPC Innovation Reports 2025 Net Loss Attributable to Shareholders

Stock News
·
Mar 16

CSPC Pharmaceutical - FY Net Loss Attributable for CSPC Innovation Pharmaceutical RMB241.1 Mln

THOMSON REUTERS
·
Mar 16